Literature DB >> 12440870

Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy.

Moses O Oyewumi1, Russell J Mumper.   

Abstract

Microemulsions (oil-in-water) have been employed as templates to engineer nanoparticles containing high concentrations of gadolinium for potential application in neutron capture therapy of tumors. Gadolinium hexanedione (GdH), synthesized by complexation of Gd(3+) with 2,4-hexanedione, was used as the nanoparticle matrix alone or in combination with either emulsifying wax or PEG-400 monostearate. Solid nanoparticles (<125 nm size) were obtained by simple cooling of the microemulsions prepared at 60 degrees C to room temperature in one vessel. The feasibility of tumor targeting via folate receptors was studied. A folate ligand was synthesized by chemically linking folic acid to distearoylphosphatidylethanolamine (DSPE) via a poly(ethylene glycol) (PEG; MW 3350) spacer. To obtain folate-coated nanoparticles, the folate ligand (0.75% w/w to 15% w/w) was added to either the microemulsion templates at 60 degrees C or nanoparticle suspensions at 25 degrees C. Efficiencies of folate ligand attachment/adsorption to nanoparticle formulations were monitored by gel permeation chromatography. Cell uptake studies were carried out in KB cells (human nasopharyngeal epidermal carcinoma cell line), known to overexpress folate receptors. The uptake of folate-coated nanoparticles was about 10-fold higher than uncoated nanoparticles after 30 min at 37 degrees C. The uptake of folate-coated nanoparticles at 4 degrees C was 20-fold lower than the uptake at 37 degrees C and comparable to the uptake of uncoated nanoparticles at 37 degrees C. Folate-mediated endocytosis was further verified by the inhibition of folate-coated nanoparticles uptake by free folic acid. It was observed that folate-coated nanoparticles uptake decreased to approximately 2% of its initial value with the coincubation of 0.001 mM of free folic acid. The results suggested that these tumor-targeted nanoparticles containing high concentrations of Gd may have potential for neutron capture therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12440870     DOI: 10.1021/bc025560x

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  9 in total

1.  Gd@C82 metallofullerenes for neutron capture therapy-fullerene solubilization by poly(ethylene glycol)-block-poly(2-(N, N-diethylamino)ethyl methacrylate) and resultant efficacy in vitro.

Authors:  Yukichi Horiguchi; Shinpei Kudo; Yukio Nagasaki
Journal:  Sci Technol Adv Mater       Date:  2011-07-07       Impact factor: 8.090

2.  A low molecular weight folate receptor targeted contrast agent for magnetic resonance tumor imaging.

Authors:  Tammy L Kalber; Nazila Kamaly; Po-Wah So; John A Pugh; Josephine Bunch; Cameron W McLeod; Michael R Jorgensen; Andrew D Miller; Jimmy D Bell
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

3.  Luminescent Silica Core / Silver Shell Encapsulated with Eu(III) Complex.

Authors:  Jian Zhang; Yi Fu; Joseph R Lakowicz
Journal:  J Phys Chem C Nanomater Interfaces       Date:  2009-11-12       Impact factor: 4.126

4.  Magnetic resonance imaging, gadolinium neutron capture therapy, and tumor cell detection using ultrasmall Gd2O3 nanoparticles coated with polyacrylic acid-rhodamine B as a multifunctional tumor theragnostic agent.

Authors:  Son Long Ho; Hyunsil Cha; In Taek Oh; Ki-Hye Jung; Mi Hyun Kim; Yong Jin Lee; Xu Miao; Tirusew Tegafaw; Mohammad Yaseen Ahmad; Kwon Seok Chae; Yongmin Chang; Gang Ho Lee
Journal:  RSC Adv       Date:  2018-04-03       Impact factor: 4.036

5.  Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug.

Authors:  Nabil F Saba; Xu Wang; Susan Müller; Mourad Tighiouart; Kwangjae Cho; Shuming Nie; Zhuo Chen; Dong M Shin
Journal:  Head Neck       Date:  2009-04       Impact factor: 3.147

Review 6.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

Review 7.  Frontiers in cancer nanomedicine: directing mass transport through biological barriers.

Authors:  Mauro Ferrari
Journal:  Trends Biotechnol       Date:  2010-01-14       Impact factor: 19.536

Review 8.  Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.

Authors:  Evelina Miele; Gian Paolo Spinelli; Ermanno Miele; Federica Tomao; Silverio Tomao
Journal:  Int J Nanomedicine       Date:  2009-04-20

Review 9.  Nanoparticles as a Tool in Neuro-Oncology Theranostics.

Authors:  Andrea L Klein; Grant Nugent; John Cavendish; Werner J Geldenhuys; Krishnan Sriram; Dale Porter; Ross Fladeland; Paul R Lockman; Jonathan H Sherman
Journal:  Pharmaceutics       Date:  2021-06-24       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.